The introduction of generic drugs, which have a chemically identical active ingredient to a brand-name drug on which patent protection has expired, has saved enormous amounts of money on drug spending. Over 85% of all prescriptions are now for generics. Biosimilars are intended to provide a generic for biologic therapies. But since those products are more complex, the cost and process for developing them is higher. And of course the drug companies are playing their usual games to prevent competition. A brief from the Pacific Research Institute’s Center for Medical Economics and Innovation explores potential savings if there was greater use of biosimilars. (Pac. Res. Paper) Off a baseline of all original biologic use, currently we are saving about $250 million through use of biosimilars. There are only 9 current therapies where a biosimilar is approved. If just for those categories, biosimilar use rose to 25%, we would save $2.5 billion, at 50% $4.8 billion and at 75%, $7.2 billion. While there may be clinical reasons why biosimilar usage would not be 100%, it should get close to that. And if biosimilar use grows dramatically, prices for those biosimilars should come down, providing even greater savings. Biosimilar development has been thwarted by drug company lobbying and lawsuits and by payoffs to biosimilar developers. Congress and the FDA need to take stronger action to facilitate, even subsidize biosimilar development and to allow payers to require their use except when clinically inappropriate. Europe has been much more aggressive in approving biosimilars and has reaped substantial savings. We should do the same.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Mental health company Headway makes, well, headway, by raising an impressive $125 million round of new capital. The company connects patients with mental health providers and facilitates providers working with...
October 11, 2023
Two health care firms owned by private equity firms are merging in a transaction supposedly valued at $3 billion. HealthComp administers self-funded plans for employers and other groups and Virgin...
September 27, 2023
NextGen, an electronic medical records firm, is being put out of its public company misery, as a PE firm will pay $1.6 billion for the one-time high-flier.
September 7, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace